Spruce Street Capital »

An2 Therapeutics shares owned by Spruce Street Capital

Quarter-by-quarter ownership of An2 Therapeutics (ANTX) shares owned by Spruce Street Capital from 13F filings

Historical chart of Spruce Street Capital investment in An2 Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including An2 Therapeutics held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in An2 Therapeutics by Spruce Street Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $8.0M 1.7M 4.84

More positions owned by Spruce Street Capital

Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Relay Therapeutics (RLAY)
Lb Pharmaceuticals Com Shs (LBRX)
Relmada Therapeutics (RLMD)
Alto Neuroscience Com Shs (ANRO)
Dianthus Therapeutics (DNTH)
Alkermes SHS (ALKS)
Savara (SVRA)
Vaxcyte (PCVX)
Enliven Therapeutics (ELVN)
Enanta Pharmaceuticals (ENTA)
Perspective Therapeutics Com New (CATX)
Inflarx Nv (IFRX)
Surrozen Com New (SRZN)
Alumis (ALMS)

View all positions for Spruce Street Capital

Top funds holding An2 Therapeutics

Vivo Capital
Commodore Capital
Millennium Management
Spruce Street Capital
Almitas Capital
Vanguard Capital Management
Adage Capital Partners GP
Woodline Partners
Boxer Capital Management
Stonepine Capital Management
Ameriprise Financial
Sio Capital Management
Ally Bridge Group
Prosight Management
Bank of America Corporation

View all funds holding An2 Therapeutics